HPV16 L1 Capsid Antibody Titers and Prognosis in HPV Associated Malignancy: Oropharyngeal, Anal, Cervical and Vaginal Cancer

D. M. Routman,K. R. Jethwa,A. E. Garda,T. A. DeWees,L. Joern,R. Hilfrich,M. C. Liu,K. A. Price,E. J. Moore,N. N. Laack,C. L. Hallemeier,R. L. Foote,I. A. Petersen,M. G. Haddock,D. J. Ma

DOI: https://doi.org/10.1016/j.ijrobp.2019.06.967

2019-01-01

Abstract:Human papillomavirus (HPV) is a primary oncogenic driver of cancers of the anal canal, uterine cervix, vagina, and oropharynx (OPX). The purpose of this study was to investigate the utility of serum HPV16 L1 capsid antibodies as a biomarker for patients treated for HPV-associated malignancy across multiple disease sites. Presence of HPV16 L1 capsid antibodies may represent a patient’s ability to mount an immune response and hold prognostic value. Furthermore, titer status could be used in follow-up to monitor disease status. Patients with newly diagnosed cancers of the anal canal, cervix, vagina, and OPX who were referred for radiotherapeutic management participated in a prospectively collected IRB approved serum biobank where-by serum was collected prior to the initiation of RT. HPV serotype 16 (HPV16) L1 capsid antibodies were quantified, and referenced to an HPV16 L1 specific antibody clone (DRH1), for which titer measurements reflect the patient’s antibody response by competing for the HPV16 specific L1 epitope. Titers ≥1000 ng/ml were considered positive (Ab+). Ab titers were quantified in a blinded fashion. Progression-free survival (PFS), and associations with Ab-status, were estimated with the Kaplan-Meier method. All statistical tests were 2-sided with p < 0.05 considered significant. A total of 133 patients were identified, including 108 evaluable patients and 25 controls. The distribution of disease sites included: 41 OPX, 33 anal canal, and 34 cervical + vaginal. Of these 108, 50% were confirmed to be p16 and/or HPV+, 3% were HPV negative, and 47% were unknown. Twenty-four of 53 (45%) of the known HPV positive cohort was Ab+. Positive Ab-titers included: OPX (46%), anal canal (30%), and cervical + vaginal (29%). Ab-status was not associated with conventional anatomical or post-operative measures of risk including clinical staging, or the presence of extranodal extension (OPX). For the OPX cohort, 47% (9 of 19) of definitive RT patients were Ab+, and 43% (10 of 23) patients post operatively were Ab+ prior to initiation of RT. Median follow-up for all patients was 20 months. Progression-free survival at 18-months was estimated to be 88% vs. 71% (p=0.16) in favor of the Ab+ cohort. Of the 25 control patients with cancers of disease sites not associated with HPV (n=10, endometrial, n=10 rectal, n=5 HPV negative OPX) along with 3 additional HPV negative patients, only 1 patient with endometrial cancer was Ab+, for a specificity of at least 96%. Serum HPV16 L1 capsid antibodies demonstrated high specificity for HPV associated cancers and deserve further investigation as a prognostic biomarker for patients with HPV-associated malignancy. Investigation of Ab titer post treatment is also warranted as a potential marker of disease status.